- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00304655
Acute Psychosis Treatment in the Long Term, Unitary Group Study (APLUS)
Multicenter, Single Group Study of Aripiprazole Efficacy and Safety in the Acute Psychosis Treatment of Schizophrenia, Schizophreniform Disorder and Schizoaffective Disorder.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This study was designed to prove safety and efficacy of aripiprazole in the treatment of acutely relapsed patients with diagnoses of schizophrenia or schizoaffective disorder in Korea and to confirm the maintenance of efficacy and safety during maintenance period and the changes in emotional factors and social functions.
After administering 15 mg/day of aripiprazole for two weeks, the test may change the dose within the range of 10 mg and 30 mg per day by clinical judgment. (Medication duration: 8 weeks (acute phase) + 18 weeks (maintenance phase)] + 26 weeks (extension phase), *total 52 weeks)
Studientyp
Einschreibung
Phase
- Phase 4
Kontakte und Standorte
Studienorte
-
-
-
Seoul, Korea, Republik von, 110-744
- Seoul National University Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Schizophrenia or schizoaffective disorder patients as defined by the DSM-IV criteria having an acute relapse
- 18 to 65 years
- Males and females (females of child bearing potential must use acceptable contraception and must not be pregnant and lactating; females of child-bearing potential must have negative serum pregnancy test)
- Randomization to this study must occur no more than four weeks following the day of initiation of treatment for the present episode/relapse.
- Should have a total PANSS score of at least 60. In addition, patients should have scores of at least 4 ("moderate") on any two of the four PANSS items that constitute the psychotic item subscale (hallucinatory behavior, delusions, conceptual disorganization, and suspiciousness).
- Patients must be able to be rated reliably on the battery of psychiatric and movement rating scales required by the protocol.
- Patients eligible to enter the study must sign an informed consent form.
Exclusion Criteria:
- Patients who are violent
- Patients who, in the opinion of the investigator, have serious suicidal ideation
- Patients who are liable to serious suicide attempt, by clinical judgment
- Patients who currently have a psychiatric diagnosis other than schizophrenia, schizophrenic form disorder or schizoaffective disorder requiring pharmacotherapy
- Patients who have any of the following neurologic diagnoses: migraine, epilepsy, Parkinson's disease, Alzheimer's disease, multiple sclerosis, residual of stroke, transient cerebral ischemic attacks, "cerebral palsy" or any other condition that requires intermittent or maintenance treatment, or which is manifested by any abnormality on neurologic examination
- Patients who must continue to take, or who may potentially need to take, during this study, any of the following concomitant medication, which could cause unwanted drug-to-drug interactions or which could confound the analysis of antipsychotic effectiveness: Tegretol (carbamazepine), Depakene Depakote (valproic acid or sodium valproate or divalproate sodium), Lithium carbonate and lithium citrate
- Patients under treatment of schizophrenia : those who had taken antipsychotic drugs (consta) before randomization
- Patients who must continue to take, during this study, drugs or substances known as strong suppressive agents of microsomal enzyme CYP2D6
- Patients with any gastrointestinal resection, stomach stapling, or any other condition that may impair the absorption of the study medication
- Patients who currently meet the DSM-IV criteria for psychoactive substance dependence or patients with a history of substance or alcohol dependence (according to the DSM-IV criteria) within one month prior to the beginning of the study
- Patients having any somatic condition whose symptoms or physical signs could be misinterpreted as signs or symptoms of psychosis or as adverse effects from antipsychotic medications.
- Patients with any acute or unstable medical condition requiring pharmacotherapy
- Patients with any abnormal laboratory test result as judged by investigator
- Patients who have participated in any previous aripiprazole clinical study
- Patients having taken an investigational drug within the four weeks which precede the start of placebo washout
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
---|
PANSS-total score (at screening, week 1, 2, 3, 4, 6, 8, 12, 16, 26, 40, 52)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
---|
[Efficacy] PANSS-positive, PANSS-negative, CGI-severity score (at screening, week 1, 2, 3, 4, 6, 8, 12, 16, 26, 40, 52)
|
[Safety] AEs (at baseline, week 1, 2, 3, 4, 6, 8, 12, 16, 26, 40, 52)
|
SAS, AIMS, Barnes (at baseline, week 1, 2, 3, 4, 6, 8, 12, 16, 26, 40, 52)
|
vital signs (at screening, baseline, week 1, 2, 3, 4, 6, 8, 12, 16, 26, 40, 52)
|
body weight (at screening, baseline, week 1, 2, 3, 4, 6, 8, 12, 16, 26, 40, 52)
|
electrocardiogram (ECG) (at screening & week 8)
|
serum prolactin concentration (at screening & week 8)
|
routine laboratory test (at screening & week 8)
|
urinalysis (at screening & week 8)
|
Pharmacokinetic is evaluated by concentration of aripiprazole in blood (at Week 3, 4, 6, 8).
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Jun-Su Kwon, Prof., Seoul National University Hospital
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Psychische Störungen
- Schizophrenie-Spektrum und andere psychotische Störungen
- Schizophrenie
- Psychotische Störungen
- Physiologische Wirkungen von Arzneimitteln
- Neurotransmitter-Agenten
- Molekulare Mechanismen der pharmakologischen Wirkung
- Depressiva des zentralen Nervensystems
- Antipsychotische Mittel
- Beruhigende Agenten
- Psychopharmaka
- Serotonin-Agenten
- Antidepressiva
- Dopamin-Agonisten
- Dopamin-Agenten
- Serotonin-5-HT1-Rezeptor-Agonisten
- Serotonin-Rezeptor-Agonisten
- Serotonin-5-HT2-Rezeptorantagonisten
- Serotonin-Antagonisten
- Dopamin-D2-Rezeptor-Antagonisten
- Dopamin-Antagonisten
- Aripiprazol
Andere Studien-ID-Nummern
- KOP-010401
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Aripiprazol
-
National Institute on Alcohol Abuse and Alcoholism...Brown UniversityAbgeschlossenAlkoholabhängigkeitVereinigte Staaten
-
Otsuka Beijing Research InstituteAbgeschlossen
-
Otsuka Pharmaceutical Co., Ltd.Abgeschlossen
-
H. Lundbeck A/SOtsuka Pharmaceutical Co., Ltd.AbgeschlossenSchizophrenieVereinigte Staaten
-
Veterans Medical Research FoundationBristol-Myers SquibbAbgeschlossen
-
Otsuka Pharmaceutical Co., Ltd.Abgeschlossen
-
Otsuka Pharmaceutical Development & Commercialization...AbgeschlossenSchizophrenieKorea, Republik von, Vereinigte Staaten, Estland, Italien, Ungarn, Bulgarien, Kroatien, Frankreich, Polen, Thailand, Puerto Rico, Chile, Südafrika, Österreich, Belgien
-
Yale UniversityRekrutierungTabak rauchenVereinigte Staaten
-
Massachusetts General HospitalBristol-Myers SquibbAbgeschlossenDepressionVereinigte Staaten
-
Central Hospital, Nancy, FranceAbgeschlossenSepsis | Kritische Krankheit | Septischer Schock | Antibiotika-ToxizitätFrankreich